Good news and bad news: its Rheumatoid arthritis drug  Humira, now the lynchpin of its spun off AbbVie, has reached sales of $9.2 billion. Humira goes off patent in 2016.


The bad news is that AbbVie's expeimental drug for chronic lymphocitic leukemia has had trials suspended due to a patient death... and trials are in limbo. AbbVie is under pressure to generate new drugs for its pipeline (who isn't?).